来源：环球市场播报 周三美股成交额第1名特斯拉收高3.31%，成交442.81亿美元。据《福布斯》周三称，特斯拉首席执行官 埃隆-马斯克成为史上首位财富达5000亿美元的人。 特斯拉将在周四公布最新季度交付数据。得益于美国消费者在本周初7，500美元电动车税收抵免到期前 的抢购潮，市场预计即将公布的交付量将为本年度最佳。然而，分析人士普遍认为，这一推动效应难以 持续，欧洲市场疲软仍将是隐忧。 第2名英伟达收高0.35%，股价再创历史新高，成交323.04亿美元。分析师称其股价受到AI芯片强劲需求 及与OpenAI达成千亿美元战略合作等利好推动。 第3名Meta Platforms收跌2.32%，成交145.75亿美元。该公司周三宣布，从用户与该公司人工智能 （AI）产品互动中收集的数据，很快将用于在其旗下各社交媒体平台推送定向广告。 Meta将在12月16日前更新隐私政策，以体现这一调整，并将在未来几天内通知用户。新政策将在全球 范围内生效，但韩国、英国及欧盟地区除外 —— 这些地区的隐私法规禁止此类数据收集行为。 第7名Palantir收高1.39%，成交83.8亿美元。 第8名礼来收高8.18%，为连续第 ...

Core Insights - Eli Lilly's stock has shown significant performance, with a 5.02% increase on September 30, marking a cumulative rise of 6.77% over three days, driven by political support, drug approvals, and market competition [1][2] Group 1: Drug Approvals and Market Impact - Eli Lilly's new Alzheimer's drug, Kisunla (donanemab), received EU market approval, enhancing its global market presence after approvals in Australia, the US, Japan, and China [1] - Kisunla targets amyloid plaques in the brain, potentially becoming an innovative therapy for Alzheimer's, with studies indicating it effectively slows cognitive and functional decline [1] - The drug's limited treatment regimen alleviates economic and medical burdens on patients, offering a new approach to healthcare systems [1] Group 2: Competitive Position in Oncology - Eli Lilly's oral selective estrogen receptor degrader, Inluriyo, has been approved by the FDA for specific breast cancer patients, showing significant advantages over traditional endocrine therapies [2] - Inluriyo is designed for estrogen receptor-positive, HER2-negative, ESR1 mutation breast cancer patients, reducing the risk of disease progression or death [2] - The company aims to enhance its competitiveness in breast cancer treatment through combination therapies and precision medicine, establishing a stronger foundation for market competition [2]